Wells Fargo & Company MN Makes New $383,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR)

Wells Fargo & Company MN bought a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 105,769 shares of the company's stock, valued at approximately $383,000. Wells Fargo & Company MN owned 0.13% of Atyr PHARMA as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ATYR. JPMorgan Chase & Co. increased its position in Atyr PHARMA by 467.8% in the fourth quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company's stock worth $646,000 after buying an additional 147,092 shares during the period. Charles Schwab Investment Management Inc. bought a new position in Atyr PHARMA in the 4th quarter worth about $144,000. American Century Companies Inc. acquired a new stake in shares of Atyr PHARMA in the fourth quarter valued at approximately $319,000. Victory Capital Management Inc. acquired a new position in shares of Atyr PHARMA during the fourth quarter worth approximately $37,000. Finally, Raymond James Financial Inc. acquired a new position in Atyr PHARMA during the 4th quarter worth $39,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Atyr PHARMA Trading Down 1.5 %

NASDAQ ATYR traded down $0.05 on Friday, hitting $3.29. 280,086 shares of the stock were exchanged, compared to its average volume of 904,514. The company's 50-day moving average price is $3.26 and its two-hundred day moving average price is $3.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. Atyr PHARMA INC has a 52-week low of $1.42 and a 52-week high of $4.66. The company has a market capitalization of $292.35 million, a price-to-earnings ratio of -3.50 and a beta of 0.79.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.02. Research analysts predict that Atyr PHARMA INC will post -0.91 EPS for the current year.

Analyst Ratings Changes

A number of research firms have commented on ATYR. Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Leerink Partners initiated coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price objective on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $35.00 target price on shares of Atyr PHARMA in a report on Friday, March 14th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Atyr PHARMA currently has an average rating of "Buy" and a consensus target price of $18.60.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.